Literature DB >> 23235762

Expression of RON in colorectal cancer and its relationships with tumor cell behavior and prognosis.

Young-Lan Park, Gi-Hoon Lee, Kyu-Yeol Kim, Eun Myung, Jong-Sun Kim, Dae-Seong Myung, Kang-Jin Park, Sung-Bum Cho, Wan-Sik Lee, Young-Do Jung, Hyun-Soo Kim, Young-Eun Joo.   

Abstract

AIMS AND
BACKGROUND: The aims of the current study were to evaluate whether recepteur d'origine nantais (RON) affects tumor cell behavior and oncogenic signaling pathways in colorectal cancer, and to examine the relationship of its expression with various clinicopathological parameters and patient survival.
METHODS: Immunohistochemistry, Western blot and RT-PCR were used to detect the expression of the RON gene in human colorectal cancer tissue. To study the biological role of RON in tumor cell behavior and cellular signaling pathways, we used small interfering RNA (siRNA) to knock down RON gene expression in human colorectal cancer cell lines.
RESULTS: Knockdown of RON inhibited the induction of the invasive growth phenotype and the activation of oncogenic signaling pathways including Akt, MAPK and β-catenin. RON overexpression was associated with tumor size, lymphovascular invasion, depth of invasion, lymph node metastasis, distant metastasis, tumor stage and poor survival.
CONCLUSIONS: These results suggest that RON overexpression may help in predicting poor clinical outcomes in colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23235762     DOI: 10.1177/030089161209800517

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916


  7 in total

Review 1.  Strategies of targeting the extracellular domain of RON tyrosine kinase receptor for cancer therapy and drug delivery.

Authors:  Omid Zarei; Silvia Benvenuti; Fulya Ustun-Alkan; Maryam Hamzeh-Mivehroud; Siavoush Dastmalchi
Journal:  J Cancer Res Clin Oncol       Date:  2016-08-08       Impact factor: 4.553

2.  RON is overexpressed in bladder cancer and contributes to tumorigenic phenotypes in 5637 cells.

Authors:  Jun-Feng Chen; Bi-Xia Yu; Liang Ma; Xiu-Yi Lv; Jun-Hui Jiang; Qi Ma
Journal:  Oncol Lett       Date:  2018-02-28       Impact factor: 2.967

3.  Monoclonal antibody Zt/g4 targeting RON receptor tyrosine kinase enhances chemosensitivity of bladder cancer cells to Epirubicin by promoting G1/S arrest and apoptosis.

Authors:  Jun-Feng Chen; Bi-Xia Yu; Rui Yu; Liang Ma; Xiu-Yi Lv; Yue Cheng; Qi Ma
Journal:  Oncol Rep       Date:  2017-01-05       Impact factor: 3.906

4.  Pathological significance of abnormal recepteur d'origine nantais and programmed death ligand 1 expression in colorectal cancer.

Authors:  Yi-Zhi Liu; Da-Ting Han; Dan-Rong Shi; Bo Hong; Yun Qian; Zhi-Gang Wu; Shu-Hao Yao; Tao-Ming Tang; Ming-Hai Wang; Xiang-Ming Xu; Hang-Ping Yao
Journal:  World J Gastrointest Oncol       Date:  2020-11-15

5.  CCL20 induces colorectal cancer neoplastic epithelial cell proliferation, migration, and further CCL20 production through autocrine HGF-c-Met and MSP-MSPR signaling pathways.

Authors:  Bisweswar Nandi; Jonathan Pastrana Del Valle; Mehmet K Samur; Allison J Gibbons; Rao H Prabhala; Nikhil C Munshi; Jason S Gold
Journal:  Oncotarget       Date:  2021-11-23

6.  Tyrosine kinase receptor RON activates MAPK/RSK/CREB signal pathway to enhance CXCR4 expression and promote cell migration and invasion in bladder cancer.

Authors:  Junfeng Chen; Kejie Wang; Shazhou Ye; Xiangyu Meng; Xiaolong Jia; Youju Huang; Qi Ma
Journal:  Aging (Albany NY)       Date:  2022-09-13       Impact factor: 5.955

Review 7.  MET and RON receptor tyrosine kinases in colorectal adenocarcinoma: molecular features as drug targets and antibody-drug conjugates for therapy.

Authors:  Hang-Ping Yao; Xiang-Min Tong; Rachel Hudson; Ming-Hai Wang
Journal:  J Exp Clin Cancer Res       Date:  2020-09-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.